Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cam4.1388 http://scihub22266oqcxt.onion/10.1002/cam4.1388 C5943466!5943466!29573207     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Med 2018 ; 7 (5): 1660-9 Nephropedia Template TP {{tp|p=29573207|t=2018. An open?label, dose?ranging study of Rolontis, a novel long?acting myeloid growth factor, in breast cancer |pdf=|usr=}}{{29573207}} gab.com Text An open label, dose ranging study of Rolontis, a novel long acting myeloid growth factor, in breast cancer JO: Cancer Med http://www.kidney.de/pget.php?&tw=1&pmid=29573207 #FOAvip This randomized, open?label, active?controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long?acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficacy endpoint was duration of severe neutropenia (DSN) during the first cycle of treatment. Patients who were candidates for adjuvant/neoadjuvant TC chemotherapy were eligible for participation. TC was administered on Day 1, followed by 45, 135, or 270 ?g/kg Rolontis or 6 mg pegfilgrastim on Day 2. Complete blood counts were monitored daily when the absolute neutrophil count (ANC) fell to <1.5 × 109/L. Up to four cycles of TC were investigated. The difference in DSN (time from ANC <0.5 × 109/L to ANC recovery ?2.0 × 109/L) between the Rolontis and pegfilgrastim groups was ?0.28 days (confidence interval [CI]: ?0.56, ?0.06) at 270 ?g/kg, 0.14 days (CI: ?0.28, 0.64) at 135 ?g/kg, and 0.72 days (CI: 0.19, 1.27) at 45 ?g/kg. Noninferiority to pegfilgrastim was demonstrated at 135 ?g/kg (P = 0.002) and 270 ?g/kg (P < .001), with superiority demonstrated at 270 ?g/kg (0.03 days; P = 0.023). The most common treatment?related adverse events (AEs) were bone pain, myalgia, arthralgia, back pain, and elevated white blood cell counts, with similar incidences across groups. All doses of Rolontis were well tolerated, and no new or significant treatment?related toxicities were observed. In Cycle 1, Rolontis demonstrated noninferiority at the 135 ?g/kg dose and statistical superiority in DSN at the 270 ?g/kg dose when compared to pegfilgrastim. Twit Text FOAVip An open label, dose ranging study of Rolontis, a novel long acting myeloid growth factor, in breast cancer ????Cancer Med http://www.kidney.de/pget.php?&tw=1&pmid=29573207 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29573207 #FOAvip English Wikipedia <ref>{{Cite pmid|29573207}}</ref> An open?label, dose?ranging study of Rolontis, a novel long?acting myeloid growth factor, in breast cancer #MMPMID29573207 Vacirca JL; Chan A; Mezei K; Adoo CS; Pápai Z; McGregor K; Okera M; Horváth Z; Landherr L; Hanslik J; Hager SJ; Ibrahim EN; Rostom M; Bhat G; Choi MR; Reddy G; Tedesco KL; Agajanian R; Láng I; Schwartzberg LS Cancer Med 2018[May]; 7 (5): 1660-9 PMID29573207show ga This randomized, open?label, active?controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long?acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficacy endpoint was duration of severe neutropenia (DSN) during the first cycle of treatment. Patients who were candidates for adjuvant/neoadjuvant TC chemotherapy were eligible for participation. TC was administered on Day 1, followed by 45, 135, or 270 ?g/kg Rolontis or 6 mg pegfilgrastim on Day 2. Complete blood counts were monitored daily when the absolute neutrophil count (ANC) fell to <1.5 × 109/L. Up to four cycles of TC were investigated. The difference in DSN (time from ANC <0.5 × 109/L to ANC recovery ?2.0 × 109/L) between the Rolontis and pegfilgrastim groups was ?0.28 days (confidence interval [CI]: ?0.56, ?0.06) at 270 ?g/kg, 0.14 days (CI: ?0.28, 0.64) at 135 ?g/kg, and 0.72 days (CI: 0.19, 1.27) at 45 ?g/kg. Noninferiority to pegfilgrastim was demonstrated at 135 ?g/kg (P = 0.002) and 270 ?g/kg (P < .001), with superiority demonstrated at 270 ?g/kg (0.03 days; P = 0.023). The most common treatment?related adverse events (AEs) were bone pain, myalgia, arthralgia, back pain, and elevated white blood cell counts, with similar incidences across groups. All doses of Rolontis were well tolerated, and no new or significant treatment?related toxicities were observed. In Cycle 1, Rolontis demonstrated noninferiority at the 135 ?g/kg dose and statistical superiority in DSN at the 270 ?g/kg dose when compared to pegfilgrastim. äAn open?label, dose?ranging study of Rolontis, a novel long?acting mye(epmc).pdf DeepDyve Pubget Overpricing